Answers are grounded in this paper and cite their sources.
This systematic review found little published evidence to support an optimal dosage regimen or TDM targets for amikacin therapy. The use of alternative approaches, such as consensus opinion and a review of current practice, will be required to develop guidelines to maximize therapeutic outcomes and minimize toxicity with amikacin.
No takes yet. Share an insight, caveat, or question.
Jenkins et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: